Nuformix moves a step closer to unlocking the commercial potential of NXP002 in idiopathic pulmonary fibrosis, securing US orphan drug designation in a market that drives the majority of global revenues.

Dr Dan Gooding explains how this regulatory milestone strengthens exclusivity, enhances partnering appeal and supports ongoing licensing discussions. With fresh funding in place, the focus now shifts to addressing due diligence questions and progressing conversations with potential partners.

The interview also outlines how NXP002’s inhaled delivery could improve efficacy while reducing side effects, positioning it against existing therapies that fall short on both outcomes and tolerability.

Nuformix is a drug development company repurposing known drugs into new, patent-protected forms for novel uses, advancing programmes to proof of concept before licensing to pharmaceutical partners.